| Autor: |
Kamran A. Ahmed, MD, Youngchul Kim, PhD, John A. Arrington, MD, Sungjune Kim, MD, PhD, Michelle DeJesus, BS, Aixa E. Soyano, MD, Avan J. Armaghani, MD, Ricardo L.B. Costa, MD, Hung T. Khong, MD, Loretta S. Loftus, MD, Marilin Rosa, MD, Jimmy J. Caudell, MD, PhD, Roberto Diaz, MD, PhD, Timothy J. Robinson, MD, PhD, Arnold B. Etame, MD, PhD, Nam D. Tran, MD, PhD, Solmaz Sahebjam, MD, Hatem H. Soliman, MD, Brian J. Czerniecki, MD, PhD, Peter A. Forsyth, MD, H. Michael Yu, MD, Hyo S. Han, MD |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Advances in Radiation Oncology, Vol 6, Iss 6, Pp 100798- (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2452-1094 |
| DOI: |
10.1016/j.adro.2021.100798 |
| Popis: |
Purpose: We hypothesize treatment with nivolumab and stereotactic radiosurgery (SRS) will be feasible and well tolerated, and may improve intracranial tumor control rates compared with SRS alone. Methods and Materials: The study was designed as a prospective, single-arm, nonrandomized, open-label, phase 1b trial of nivolumab and SRS among patients with metastatic breast cancer brain metastases. Key eligibility criteria included patients with breast cancer brain metastases of all subtypes, age ≥18, Eastern Cooperative Oncology Group Performance Status ≤2 with ≤10 brain metastases. Treatment was initiated with a dose of nivolumab (480 mg intravenously) that was repeated every 4 weeks. The initial dose of nivolumab was followed 1 week later by SRS. This study is closed to accrual and is registered with ClinicalTrials.gov, NCT03807765. Results: Between February 2019 and July 2020, a total of 12 patients were treated to 17 lesions. No dose limiting toxicities were noted in our patient population. The most common neurologic adverse events included grade 1 to 2 headaches and dizziness occurring in 5 (42%) of patients. Median intracranial control was 6.2 months (95% confidence interval, 3-14 months) with 6- and 12-month control rates of 55% and 22%, respectively. A total of 4 patients had systemic progression during the study. Median time to systemic progression free survival has not been reached with 6- and-12 month rates of 63% and 51%, respectively. Conclusions: Nivolumab and SRS is a safe and feasible treatment option in breast cancer brain metastases. Preliminary data reveals activity in certain breast cancer patients to study therapy. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
